Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotech Sequenom
So what: The company's Trisomy 21 (T21) test promises a non-invasive means to test for Down syndrome in unborn children. According to the earnings release, results for the latest round of T21 results won't be published until later this year.
Now what: In the meantime, Sequenom's first quarter ended with a $0.13-per-share loss on $13.5 million in revenue. Analysts had been expecting a $0.19-per-share loss on $12.7 million in revenue. Traders and investors alike cheered. But for Fools, this three-star stock remains a speculative bet. Tread carefully.
Interested in more info on Sequenom? Add it to your watchlist.
Tim didn't own shares in any of the companies mentioned in this article at the time of publication. Check out his portfolio holdings and Foolish writings, or connect with him on Twitter as @milehighfool. You can also get his insights delivered directly to your RSS reader. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool is also on Twitter as @TheMotleyFool. Its disclosure policy is at least 10% better than other disclosure policies.